The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS....
Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscor...
Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PR...
CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
CAMBRIDGE, Mass. , May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (...
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAM...
CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd....